The 7.7% dividend is not covered by free cash flow (FCF $384M vs $1.76B paid) — a cut would break the income thesis
One-line thesis. LyondellBasell is a well-run commodity-chemicals major caught in the worst petrochemical down-cycle in a decade — it lost money on a TTM basis, shut its Houston refinery, and is paying a 7.7% dividend it did not earn in cash last year; the stock is genuinely cheap on normalized mid-cycle earnings, but "cheap" here is a bet on a cycle turn plus dividend survival, not a quality compounder, so we rate it Watch.
◆ Synthos call — AvoidLYB's problem is the business, not the price — weak growth and/or a deteriorating trajectory; a cheaper quote alone won't change our mind.
Downside Risk (lower = safer)
8/10 · Very High
Deep cyclical trough — TTM loss, net-debt/EBITDA ~10×, 7.7% yield NOT covered by FCF (0.22×), RSI 13.6.
Growth Quality
3/10 · Low
FY25 revenue -25% (refinery shut), TTM net margin -2.7%, ROIC negative; earnings are cycle-driven, not compounding.
Exponential Potential
2/10 · Low
Commodity petrochemicals — no acceleration, no secular TAM expansion; the only upside is mean-reversion off a trough.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ -1%/yrTo justify today’s $53, earnings would have to compound roughly -1% a year for 10 years (9% discount rate). Analysts forecast ~-13%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
LyondellBasell makes the basic plastics and chemicals that go into almost everything — packaging, pipes, car parts, paint, fuel additives. It doesn't invent fancy products; it makes commodities, so its profits swing wildly with the economy and with the price of oil and natural gas. Right now the industry is in a slump: too much supply, weak demand, thin margins. The company actually lost money over the last year and shut down its big Houston oil refinery.
Is the stock cheap? Yes — but for a reason. It has fallen about 35% from its high and pays a fat 7.7% dividend. The problem: last year the company did not generate enough spare cash to cover that dividend, so there's a real chance the dividend gets cut. That's the single biggest worry.
Our verdict is Watch — meaning "interesting, but wait." It could bounce hard if the chemical cycle turns up, but you'd be catching a falling knife with a possible dividend cut in front of you.
Here's what our three scores mean in everyday terms:
Downside Risk 8/10 (high). Lots of debt, a dividend it can't currently afford, and a stock in a clear downtrend. This is the risky end of the S&P 500.
Growth Quality 3/10 (poor). Profits go up and down with the economy; there's no steady, reliable growth here.
Exponential Potential 2/10 (very low). This is a boring commodity business. The best case is a rebound to normal, not a moonshot.
The one big worry: the dividend may be cut, and the industry slump could last longer than the bulls hope.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = LYB · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$53.36
Market cap$17B
P/E trailing2×
P/E FY26E / FY27E6× / 7×
EV / Sales1.0×
EV / EBITDA22.0×
Gross margin9.7%
Net margin-2.7%
Dividend yield7.72%
Beta0.328
52-wk range$42 – $82
RSI(14)14
50 / 200-DMA$67 / $57
12-mo return+-13% (SPY +21%)
Street target$77 ($62–$91)
Analyst grades16 Buy · 18 Hold · 4 Sell
FMP ratingC
Next earnings2026-08-05
What the experts actually said 0 traceable claims on LYB · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
LyondellBasell (NYSE: LYB) is one of the world's largest commodity petrochemical and plastics producers, headquartered in Houston and incorporated in the Netherlands. It converts oil- and gas-derived feedstocks (ethane, naphtha, propylene) into the building-block plastics and chemicals that the world runs on. The business is organized into five/six operating segments: Olefins & Polyolefins–Americas, Olefins & Polyolefins–Europe/Asia/International, Intermediates & Derivatives, Advanced Polymer Solutions, and Technology (process licensing & catalysts). Fiscal year ends December 31. ~20,000 employees. CEO Peter Vanacker.
This is a classic deep cyclical: margins are set by the global spread between feedstock cost and polymer/chemical selling prices, which swings with the economy, energy prices, and industry capacity additions. It is not a secular-growth story.
Revenue mix (FY2025, from filings):
By product: Polyethylene $7.20B (24%) · Polypropylene $5.85B (19%) · Oxyfuels & related $4.83B · Olefins & co-products $4.18B · Compounding & solutions $3.46B · Intermediates & derivatives $1.89B. Note: FY2024 also carried Refined Products $8.08B — that line is gone in FY2025 because LYB exited/idled its Houston refinery, which is the main reason revenue fell from $40.3B to $30.2B (−25%).
By geography (reportable): United States $11.06B · Germany $2.20B · China $1.78B · Mexico $1.56B · Italy $1.32B · Japan $1.26B · France $1.16B · Poland $0.79B · Netherlands $0.73B · non-reportable $8.29B. Genuinely global, with heavy US and European exposure (European petrochemicals are the weakest region — see §9).
2. The expert thesis — (none in the Synthos KB)
There is no expert coverage of LYB in the Synthos knowledge base.total_claims = 0, net_bullish_voices = 0, and the top list is empty. Unlike our conviction-track names, there are no claim_id values to cite, and per the House Standard we will not manufacture any.
Accordingly, this verdict is entirely fundamentals- and quant-driven: it rests on the reported financials, the analyst-estimate consensus (labeled as estimates), the balance sheet, the dividend-coverage math, and the technical picture — nothing else. Readers should weight this note as a data-and-valuation call, not as an expert-panel conviction call. For context, the external sell-side is lukewarm: FMP letter rating "C" (overall score 2/5), and the analyst-grade consensus is Hold (1 Strong Buy, 16 Buy, 18 Hold, 4 Sell).
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
8 · High
TTM net loss; net-debt/EBITDA ~10× on trough EBITDA (~8.8× on TTM); FCF $384M does not cover the $1.76B dividend (0.22× coverage) → cut risk; RSI 13.6 in a −35%-off-high downtrend. Only the low 0.33 beta and 0.97× EV/sales keep this from a 9.
Growth Quality
3 · Poor
FY25 revenue −25% (refinery exit + price weakness), TTM net margin −2.7%, ROIC and ROE negative. Earnings are cyclical, not compounding; the "growth" in FY26E estimates is cycle-recovery, not durable expansion.
Exponential Potential
2 · Low
Commodity petrochemicals — no acceleration, no secular TAM. The circular-plastics/recycling initiative is real but small and years from moving the needle. Upside is mean-reversion off a trough, which caps the score.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities. Because LYB is a trough cyclical, we anchor on normalized mid-cycle EPS rather than a single forward year — trailing EPS is negative and the FY26E consensus ($9.16) looks optimistic against the actual quarterly run-rate (Q1'26 diluted EPS $0.38, Q2'26 Street est $3.21).
Case
Key assumptions
Fair value
Bull
Chemical cycle inflects in 2026–27; polyolefin spreads normalize; Cash Improvement Program delivers; dividend held. Normalized EPS ~$8.5 at a mid-cycle ~9×.
~$78 (+46%)
Base(our anchor)
Slow, partial cycle recovery; normalized mid-cycle EPS ~$6.0 at a trough-appropriate ~9×; dividend maintained but not growing.
~$55 (+3%)
Bear
Down-cycle persists into 2027; European assets keep bleeding; dividend is cut to protect the balance sheet; multiple stays depressed. Normalized EPS ~$4.5 at ~7.5×.
~$34 (−36%)
Synthos fair value = the base case, ~$55 (+3%), with the full $34–$78 span as the honest range. This anchor sits well below the Street's $76.6 consensus: we think the sell-side is anchoring on a cycle recovery (and the stale-looking FY26E $9.16 EPS) that the cash flows do not yet support, and we take the dividend-cut and prolonged-trough risks seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures. Base-case upside is roughly flat, which is exactly why the verdict is Watch, not Buy.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). LYB is neither — it is a mature, capital-intensive commodity cyclical:
Forward growth is cyclical, not secular: revenue fell from $50.5B (2022) to $41.1B (2023) to $40.3B (2024) to $30.2B (2025). The forward estimates ($34B FY26E → $33B FY27E → $32B FY28E) represent a modest bounce off a trough, not a growth ramp.
Acceleration (2nd derivative): there is no positive earnings acceleration — quarterly EBITDA swung from +$1.28B (Q3'24) to −$0.37B (Q3'25) and back to +$0.62B (Q1'26). This is spread volatility, not a trend.
Room to run vs TAM: the addressable market (global plastics/chemicals) is enormous but mature and oversupplied — new Middle East and Chinese capacity is the structural headwind, not a tailwind. Scale here is a cost position, not a growth runway.
Optionality: the circular-economy / advanced-recycling and MoReTec pyrolysis initiatives are genuine and strategically sensible, but they are small today and years from materially changing the earnings mix.
Exponential Potential: Low (2/10). Own LYB — if at all — for deep-cyclical mean-reversion and dividend income, never for compounding. There is no honest multibagger case here.
Revenue: FY25 $30.15B, −25.2% (FY24 $40.30B, itself −2% on FY23 $41.11B). The FY25 drop is dominated by the Houston refinery exit (Refined Products $8.08B → $0) plus soft polyolefin pricing.
Quarterly trajectory (the cycle in one line): Q1'25 $7.68B → Q2 $7.66B → Q3 $7.73B → Q4 $7.09B → Q1'26 $7.20B. Roughly flat-to-down at ~$7.2–7.7B/qtr — a trough plateau, not a recovery yet.
Margins (thin and cyclical): gross 9.7% TTM, EBITDA margin 4.4% TTM, operating margin −0.3%, net margin −2.7% TTM. FY24 was healthier (EBITDA $3.61B, net income $1.36B); FY25 collapsed (EBITDA $1.19B, net loss −$743M).
Earnings: FY25 net loss −$743M, EPS −$2.35 (vs +$4.16 FY24, +$6.48 FY23, +$11.84 in the 2022 peak). Q3'25 alone was a −$2.77 EPS loss (impairments/identified items). Q1'26 returned to a small profit ($0.38 diluted / $0.49 per earnings calendar).
Cash flow (the crux): FY25 operating CF $2.26B, capex −$1.88B, FCF just $384M — against $1.76B of dividends paid. Dividend coverage from FCF was 0.22×; the shortfall was funded with +$1.48B of net new debt. This is not sustainable indefinitely.
Balance sheet: total debt $15.96B, net debt $12.51B (up from $9.55B a year ago), net-debt/EBITDA ~8.8× on TTM EBITDA (~10× on FY25) — elevated because EBITDA is trough-depressed. Current ratio 1.54× and $3.45B cash provide near-term liquidity, and the debt is investment-grade, but leverage is the key watch-item until EBITDA recovers.
6. Valuation — cheap, but a value trap risk
On trailing numbers LYB screens statistically cheap: 0.58× sales, 0.97× EV/sales, 1.7× book, 7.7% dividend yield, and a 16% trailing FCF yield (flattered by low capex-to-D&A in FY25). Trailing P/E is meaningless (negative EPS). The bull case is normalization: if the FY26E consensus EPS of $9.16 is anywhere close to right, the forward P/E is ~5.8× and EV/EBITDA drops to ~7.5× — genuinely cheap for a global #1/#2 producer.
The honest caveats: (1) that FY26E estimate looks optimistic versus the actual run-rate — Q1'26 came in at $0.38–$0.49 and the Street's own Q2'26 estimate is $3.21, so the annual figure leans heavily on a big second-half recovery that has not shown up in the cash flows yet; (2) EV/EBITDA of 22× on TTM reflects a trough denominator, not a rich price; (3) the 7.7% yield is a classic value-trap signal when it isn't covered by FCF. Street targets (context): consensus $76.6, high $91, low $62 — our $55 base FV is deliberately below the Street because we discount the recovery pace and the dividend risk. This is cheap-for-a-reason, not a clean bargain.
7. Technicals (from the tech block)
Trend: down. $53.36 sits below both the 50-DMA ($66.92) and 200-DMA ($57.31), and the 50 is below the 200 (death-cross posture). MACD −4.11 (negative).
Location:−35.2% off the 52-week high ($82.38), +26.2% off the 52-week low ($42.28); max drawdown −54.7% from peak — a severe bear market in the shares.
Momentum: RSI(14) 13.6 — deeply oversold (well below 30). That flags a stretched-to-the-downside condition that can produce sharp counter-trend bounces, but oversold ≠ bottom; it confirms the sellers are in control.
Relative strength (the tell): LYB −12.8% 12-mo vs SPY +20.6% and QQQ +30.3%; −30.4% 3-mo vs SPY +13.7%. Persistent, heavy underperformance of both the market and its cyclical peers.
Read: technicals contradict any near-term bull case — this is a downtrend, not a base. The deeply oversold RSI is the only constructive signal, and only for a possible tactical bounce. No technical "all-clear" for a long-term entry yet; a stabilization above the 200-DMA (~$57) would be the first real sign.
8. Moat & competitive position
LYB's competitive edge is cost and scale, not a durable moat: it runs among the industry's most efficient US ethane-based crackers (a structural feedstock-cost advantage vs naphtha-based competitors) and has a leading global polyolefins position plus a valuable Technology/licensing franchise (Spheripol/Spherizone process licensing and catalysts, which is high-margin and counter-cyclical). But commodity chemicals have no pricing power — products are fungible, and the industry is being flooded by new low-cost capacity in the Middle East and China. European assets are structurally disadvantaged (high energy costs) and LYB is actively reviewing/restructuring them.
Peer set (market cap): Dow $20.0B (the closest US commodity-chem comp), DuPont $18.9B, Albemarle $16.0B, CF Industries $17.0B, Westlake $9.6B, SQM $20.8B, IFF $21.4B, Reliance Steel $19.0B, RPM $14.2B, Cemex $17.8B. LYB and Dow are the two most direct read-throughs; both are trading through the same petrochemical trough, so peer weakness corroborates that this is a sector cycle, not a company-specific stumble.
9. Management, capital allocation & guidance
Capital allocation: the pressure point. Management is defending a 7.7% dividend (FY25 payout of $1.76B) that FY25 FCF ($384M) did not cover, funding the gap with new debt. It has also launched a Cash Improvement Plan / Value Enhancement Program to cut costs and lift normalized EBITDA, and has been rationalizing the weakest assets (Houston refinery exit; European review). Buybacks are minimal ($201M FY25). The strategy is reasonable for a trough, but the dividend is the item most likely to give.
Insider activity: the sampled Form 4s (May–June 2026) are routine director equity awards and in-kind tax withholdings at ~$69.72 — housekeeping, no meaningful open-market buying or alarming discretionary selling in the window.
Management's own guidance (half-weighted by design — they talk their own book): the latest SEC 8-K earnings material (filed 2026-05-01, Q1'26) is a segment business-results discussion, not a formal forward revenue/EPS outlook. Management's own words describe Q1'26 as an improvement off the Q4'25 trough: O&P-Americas EBITDA rose to $327M on "higher integrated margin from pricing actions following year-end destocking and global supply disruptions," with crackers running "at maximum rates" (~75% ethane); O&P-EAI (Europe/Asia) remained a loss (−$35M EBITDA); I&D improved on propylene-oxide and styrene margins; Technology licensing was weaker. Net: management frames Q1'26 as a bottoming, feedstock-advantaged quarter, but issued no explicit forward numeric guidance in this release — so we do not attribute a forward revenue/EPS target to management. Treat the operational commentary as self-interested and half-weighted.
10. Catalysts & what to watch
Next earnings: 2026-07-31 (Q2'26; Street EPS $3.21, revenue ~$9.3B — note that estimate looks high vs the recent run-rate; a miss is a real risk). The key lines: polyolefin spreads / integrated margin and any dividend commentary.
The dividend decision: the single biggest catalyst either way. A reaffirmation with improving FCF is bullish; a cut removes the income thesis but could de-risk the balance sheet.
Petrochemical cycle data: ethylene/polyethylene spreads, global operating rates, and the pace of new Middle East/China capacity coming online.
European asset restructuring: decisions on idling/selling loss-making EAI assets would improve normalized margins.
Cash Improvement / Value Enhancement Program: evidence it is actually lifting normalized EBITDA toward management's targets.
Thesis tripwires (what would change the call): a dividend cut (bear confirmation, but re-rate the balance sheet); two more quarters of negative FCF; net-debt/EBITDA staying above ~5× as EBITDA fails to recover; or, on the upside, two consecutive quarters of expanding integrated margin with FCF re-covering the dividend (which would move this toward Buy — Tactical).
11. Key risks
Dividend cut (the headline risk): 7.7% yield, 0.22× FCF coverage in FY25, funded by new debt — mathematically stretched.
Prolonged down-cycle / oversupply: structural new capacity in the Middle East and China can keep spreads depressed for years; this is not guaranteed to be a quick V-shaped recovery.
Leverage: net-debt/EBITDA ~8.8–10× on trough EBITDA; a longer trough pressures the credit profile and could force further asset sales.
European exposure: high-cost EAI assets are loss-making and a drag until restructured.
Commodity / energy price swings: earnings are levered to the oil/gas-to-polymer spread, which LYB does not control.
Value-trap risk: statistically cheap stocks in secularly-pressured commodity industries can stay cheap or get cheaper — the downtrend (RSI 13.6, −54% max drawdown) says the market is not yet convinced.
No expert corroboration: zero Synthos KB coverage means no independent conviction layer beneath this call.
12. Verdict, position sizing & monitoring
Watch. LyondellBasell is a well-run, low-cost commodity-chemicals major trading at genuinely low multiples of sales and normalized earnings — but it is doing so for real reasons: a TTM loss, a refinery exit that gutted reported revenue, trough-level margins, ~9–10× trough leverage, and a 7.7% dividend it did not cover in cash last year. The base-case fair value (~$55) is essentially flat to today's price, and the honest range ($34–$78) is wide and cycle-dependent. That asymmetry — limited base-case upside, a live dividend-cut risk, and a confirmed downtrend — is a Watch, not a Buy. There is no expert-panel conviction beneath it either; this is a pure fundamentals/quant call.
Sizing: if an income/deep-value investor owns it at all, a small 1–2% cyclical satellite, explicitly sized to survive a dividend cut and a longer trough — never a core position. Most investors should simply watch for the cycle turn.
What would upgrade it: to Buy — Tactical, we'd want two consecutive quarters of expanding integrated margin, FCF re-covering the dividend, and price stabilizing back above the 200-DMA (~$57). To Avoid, a dividend cut combined with a still-worsening spread environment.
Monitoring: re-underwrite on the 2026-07-31 print and each subsequent quarter; formal re-score on any dividend action. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $53.36.
Single biggest risk: the uncovered 7.7% dividend — a cut would break the income case and is the most probable near-term shock.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — there is no expert coverage of LYB in the Synthos knowledge base, so no claim_id values are cited and none were fabricated. This is a fundamentals- and quant-driven verdict built on FMP financials, analyst estimates (labeled as estimates), and the SEC 8-K earnings material.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management commentary from the 2026-05-01 8-K (Q1'26). Forward figures are analyst consensus (FMP) or our own scenario assumptions, and are labeled as estimates.
Management caveat: the Q1'26 8-K is a segment results discussion, not formal numeric guidance; management commentary is self-interested and half-weighted by design.
Estimate-quality flag: the FY26E consensus EPS ($9.16) appears optimistic versus the reported quarterly run-rate; we have deliberately anchored our base case on normalized mid-cycle EPS instead.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").